| Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study LG Hemkens, U Grouven, R Bender, C Günster, S Gutschmidt, GW Selke, ... Diabetologia 52, 1732-1744, 2009 | 821 | 2009 |
| Policies for biosimilar uptake in Europe: an overview E Moorkens, AG Vulto, I Huys, P Dylst, B Godman, S Keuerleber, B Claus, ... PloS one 12 (12), e0190147, 2017 | 255 | 2017 |
| Drug utilization research: methods and applications M Elseviers, B Wettermark, T Mueller, R Benko, M Bennie, K Gvozdanovic, ... John Wiley & Sons, 2024 | 183 | 2024 |
| Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets B Godman, A Bucsics, PV Bonanno, W Oortwijn, CC Rothe, A Ferrario, ... Frontiers In Public Health 6 (DEC), 2018 | 181 | 2018 |
| Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? B Godman, RE Malmström, E Diogene, A Gray, S Jayathissa, A Timoney, ... Expert review of clinical pharmacology 8 (1), 77-94, 2015 | 169 | 2015 |
| The German experience in reference pricing G Giuliani, G Selke, L Garattini Health policy 44 (1), 73-85, 1998 | 164 | 1998 |
| Personalizing health care: feasibility and future implications B Godman, AE Finlayson, PK Cheema, E Zebedin-Brandl, ... BMC medicine 11, 1-23, 2013 | 129 | 2013 |
| Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs RE Malmström, BB Godman, E Diogene, C Baumgärtel, M Bennie, ... Frontiers in pharmacology 4, 39, 2013 | 122 | 2013 |
| The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ... Frontiers In Pharmacology 11, 1-17, 2021 | 80 | 2021 |
| Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications B Godman, A Hill, S Simoens, G Selke, I Selke Krulichová, ... Expert review of pharmacoeconomics & outcomes research 21 (4), 527-540, 2021 | 76 | 2021 |
| Improving the managed entry of new medicines: sharing experiences across Europe B Godman, K Paterson, RE Malmström, G Selke, JP Fagot, J Mrak Expert review of pharmacoeconomics & outcomes research 12 (4), 439-441, 2012 | 76 | 2012 |
| Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe W Matusewicz, B Godman, HB Pedersen, J Fürst, J Gulbinovič, A Mack, ... Expert review of pharmacoeconomics & outcomes research 15 (5), 755-758, 2015 | 69 | 2015 |
| Payers' views of the changes arising through the possible adoption of adaptive pathways M Ermisch, A Bucsics, P Vella Bonanno, F Arickx, A Bybau, T Bochenek, ... Frontiers in pharmacology 7, 305, 2016 | 68 | 2016 |
| What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? S Schneeweiss, O Schöffski, GW Selke Health Policy 44 (3), 253-260, 1998 | 67 | 1998 |
| Dabigatran-a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs B Godman, RE Malmström, E Diogene, S Jayathissa, S McTaggart, T Cars, ... Frontiers in pharmacology 5, 109, 2014 | 62 | 2014 |
| Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs B Godman, U Schwabe, G Selke, B Wettermark Pharmacoeconomics 27, 435-438, 2009 | 59 | 2009 |
| Integrative review of managed entry agreements: chances and limitations C Zampirolli Dias, B Godman, LP Gargano, PS Azevedo, MM Garcia, ... Pharmacoeconomics 38, 1165-1185, 2020 | 57 | 2020 |
| Pricing of oral generic cancer medicines in 25 European countries; findings and implications B Godman, A Hill, S Simoens, A Kurdi, J Gulbinovič, A Martin, A Timoney, ... Generics and Biosimilars Initiative Journal 8 (2), 49-70, 2019 | 57 | 2019 |
| Non‐antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries F De Ponti, E Poluzzi, A Vaccheri, U Bergman, L Bjerrum, J Ferguson, ... British journal of clinical pharmacology 54 (2), 171-177, 2002 | 56 | 2002 |
| Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: A prescription‐based analysis M Ufer, SA Meyer, O Junge, G Selke, HP Volz, J Hedderich, CH Gleiter Pharmacoepidemiology and drug safety 16 (10), 1153-1160, 2007 | 55 | 2007 |
